Table 2.

Summary of pharmacodynamic results.

Efficacy variable	Treatment	n	Baseline Mean	Adjusted⋆⋆ mean change from baseline (s.e. mean)	95% CI vs placebo	One-sided P value vs placebo	95% CI for ebastin vs terfenadine	Two-sided P value vs terfenadine
	Placebo	25	383.8	1.4 (2.5)
Mean QTcB	Ebastine 60 mg	24	384.8	3.7 (2.5)	[−2.86, 7.46]	0.2427	[−19.46, −9.14]	0.0000⋆
(ms)	Ebastine 100 mg	25	380.9	10.3 (2.5)	[3.75, 14.05]	0.0034⋆	[−12.86, −2.54]	0.0195⋆
	Terfenadine	24	382.7	18.0 (2.5)	[11.44, 21.76]	0.0000⋆
	Placebo	25	381.7	−2.1 (2.1)
Mean QTcF	Ebastine 60 mg	24	383.2	−3.2 (2.1)	[−5.43, 3.23]	0.2765	[−21.63, −12.97]	0.0001⋆
(ms)	Ebastine 100 mg	25	379.8	1.5 (2.1)	[−0.73, 7.93]	0.1490	[−16.93, −8.27]	0.0001⋆
	Terfenadine	24	381.3	14.1 (2.1)	[11.87, 20.53]	0.0001⋆
	Placebo	25	378.3	−8.9 (2.4)
Mean QT	Ebastine 60 mg	24	380.5	−17.0 (2.5)	[−13.16, −3.04]	0.9877	[−28.16, −17.84]	0.0000⋆
(ms)	Ebastine 100 mg	25	378.3	−15.2 (2.4)	[−11.24, −1.36]	0.9630	[−26.26, −16.14]	0.0000⋆
	Terfenadine	24	379.0	6.0 (2.5)	[9.84, 19.96]	0.0000⋆
	Placebo	25	62.5	3.5 (1.0)
Mean HR	Ebastine 60 mg	24	62.0	7.6 (1.0)	[2.04, 6.16]	0.0020⋆	[1.5, 44.56]	0.0128⋆
(ms)	Ebastine 100 mg	25	61.5	9.3 (1.0)	[3.74, 7.86]	0.0000⋆	[3.7, 14.26]	0.0003⋆
	Terfenadine	24	61.9	4.1 (1.0)	[−1.46, 2.66]	0.3367

^⋆P values < 0.05.

^⋆⋆Adjusted for imbalance of primary population in each treatment.